Tag Archives: Merck

Merck to Close Eight Plants

By Oriana Schwindt | Published: July 8, 2010
Image by Getty Images via @daylife Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.” Taking a page out of Pfizer’s book [...]
Posted in Strategy | Also tagged , , , , , , | 3 Comments

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment

Cold Cuts: Merck Layoffs Loom

By Reid Paul | Published: January 7, 2010
Image via Wikipedia It is not just cold outside these days, as Merck & Co. makes some cold hard decisions. Following on the heels of its now closed acquisition of Schering-Plough, Merck is making significant job cuts across its operations. Some 16,000 jobs are expected to be eliminated in total as a result of the merger. According [...]
Posted in Strategy | Also tagged , , , | Leave a comment

Merck, Schering-Plough Merger Boosts Global Profile, but Questions Linger

By Andrew Sheivachman | Published: November 5, 2009
Image via Wikipedia After Merck & Co. officially announced its $41.1 billion merger with Schering-Plough yesterday, CEO Richard Clark made it clear his company is still looking to expand through further acquisitions and mergers. According to the Wall Street Journal’s Health Blog: Clark told us today that the newly combined company  is “actively looking” for biotechs to [...]
Posted in Strategy | Also tagged , , , , , , | 2 Comments

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments